Download This Paper
Preprints with The Lancet is a collaboration between The Lancet Group of journals and SSRN to facilitate the open sharing of preprints for early engagement, community comment, and collaboration. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early-stage research papers that have not been peer-reviewed. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. The findings should not be used for clinical or public health decision-making or presented without highlighting these facts. For more information, please see the FAQs.
Sentinel Lymph Node Biopsy and Morbidity Outcomes in Early Cervical Cancer: Results of a Multicenter Randomized Trial (Senticol II)
87 Pages Posted: 16 Jul 2020
More...Abstract
Background: Pelvic lymph-node dissection has been the standard of care for patients with early cervical cancer. Sentinel node (SN) mapping is safe and feasible and may increase detection of metastatic disease.
Methods: In an open-label study, patients with early cervical carcinoma (FIGO 2009 stage IA2 to IIA1) were randomly assigned to SN resection alone (SN arm) or SN and pelvic lymph node dissection (SN+PLND arm). SN resection was followed by radical surgery of the tumor (radical hysterectomy or radical trachelectomy). The primary endpoint was morbidity related to the lymph-node dissection; 3-year recurrence-free survival was a secondary endpoint.
Findings: A total of 206 patients were eligible and randomly assigned to the SN arm (105 patients) or SN+PLND arm (101 patients). The majority of patients had stage IB1 lesion (87.4%). No false negative case was observed in SN+PLND arm. Lymphatic morbidity was significantly lower in the SN arm (31.4%) than in the in SN+PLND arm (51.5%; p=0.0046), as was the rate of post-operative neurological symptoms (7.8% vs. 20.6%, p=0.01; respectively). During the 6-month post-operative period, the difference in morbidity decreased over time. The 3-year recurrence-free survival was not significantly different (92.0% in SN arm and 94.4% in SN+PLND arm).
Interpretation: SN resection alone is associated with decreased lymphatic morbidity when compared with SN+PLND in early cervical cancer, without compromising the 3-year recurrence-free survival.
Trial Registration: (Clinicaltrials #NCT01639820)
Funding: The study was supported by the French National Cancer Institute (STIC 2008 & 2012).
Declaration of Interests: The authors have no potential conflict of interest related to this publication to disclose.
Ethics Approval Statement: SENTICOL-II was approved by an ethics committee (Comité de Protection des Personnes Sud-Est IV, decision A08-223), and all patients provided written informed consent before inclusion.
Keywords: Uterine cervical neoplasm; sentinel node biopsy; lymphadenectomy; morbidity; quality of life
Suggested Citation: Suggested Citation